Introduction: Lenvatinib was the first drug approved in 2017 for first-line treatment of hepatocarcinoma (HCC) after 10 years of Sorafenib as exclusive standard of care. The therapeutic armamentarium has recently expanded following the approval of atezolizumab plus bevacizumab. Areas covered: Numerous studies have been conducted during the past 5 years on Lenvatinib use in real-world settings in an effort to determine prognostic and predictive factors of Lenvatinib efficacy. In order to choose the most effective therapeutic approach, it may be helpful to summarize these results in this review. Expert opinion: A subgroup that appears to benefit most from Lenvatinib therapy are patients with non-viral cirrhosis. This aspect is of great importance today considering the increase in NASH prevalence. Also, a significant proportion of BCLC B patients appear to respond well to Lenvatinib therapy. The biological heterogeneity highlighted in HCC patients, along with the growing number of therapeutic options, makes the identification of stratification tools able to define which patients are more likely to respond to a treatment rather than another one of crucial interest. Further investigation deepening the biological pathways underlying HCC carcinogenesis are of particular interest in order to pave the way for precision medicine even for HCC patients.

Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors?

Scartozzi, Mario;
2023-01-01

Abstract

Introduction: Lenvatinib was the first drug approved in 2017 for first-line treatment of hepatocarcinoma (HCC) after 10 years of Sorafenib as exclusive standard of care. The therapeutic armamentarium has recently expanded following the approval of atezolizumab plus bevacizumab. Areas covered: Numerous studies have been conducted during the past 5 years on Lenvatinib use in real-world settings in an effort to determine prognostic and predictive factors of Lenvatinib efficacy. In order to choose the most effective therapeutic approach, it may be helpful to summarize these results in this review. Expert opinion: A subgroup that appears to benefit most from Lenvatinib therapy are patients with non-viral cirrhosis. This aspect is of great importance today considering the increase in NASH prevalence. Also, a significant proportion of BCLC B patients appear to respond well to Lenvatinib therapy. The biological heterogeneity highlighted in HCC patients, along with the growing number of therapeutic options, makes the identification of stratification tools able to define which patients are more likely to respond to a treatment rather than another one of crucial interest. Further investigation deepening the biological pathways underlying HCC carcinogenesis are of particular interest in order to pave the way for precision medicine even for HCC patients.
2023
BCLC stage
HCC etiology
Lenvatinib
adverse events
dose intensity
hepatocellular carcinoma
predictive factors
prognostic factors
tyrosine kinase inhibitor
File in questo prodotto:
File Dimensione Formato  
Five years of lenvatinib in hepatocellular carcinoma are there any predictive and or prognostic factors.pdf

Solo gestori archivio

Tipologia: versione editoriale (VoR)
Dimensione 610.59 kB
Formato Adobe PDF
610.59 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
AMFive+years+of+lenvatinib+in+hepatocellular+carcinoma+are+there+any+predictive+and+or+prognostic+factors.pdf

Open Access dal 01/02/2024

Tipologia: versione post-print (AAM)
Dimensione 461.73 kB
Formato Adobe PDF
461.73 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/356998
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact